These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 4328099

  • 1. Cerebral catecholamine concentration after L-dopa therapy in Parkinson's disease.
    Greer M, Anton AH.
    Trans Am Neurol Assoc; 1970; 95():247-8. PubMed ID: 4328099
    [No Abstract] [Full Text] [Related]

  • 2. [Study of dopamine and noradrenaline in the brains of three patients with Parkinson's disease who died in the course of treatment with L-dopa].
    Buscaino GA, Sori A, Campanella G.
    Rev Neurol (Paris); 1972 Aug; 127(2):301-2. PubMed ID: 4666634
    [No Abstract] [Full Text] [Related]

  • 3. [Parkinson's syndrome. 1. Biochemistry of the monoamines].
    Roos BE.
    Lakartidningen; 1970 Oct 14; 67(42):4803-6. PubMed ID: 5483442
    [No Abstract] [Full Text] [Related]

  • 4. [10 years of L-DOPA therapy of Parkinson's syndrome].
    Birkmayer W.
    Wien Klin Wochenschr; 1971 Apr 02; 83(13):221-7. PubMed ID: 4254333
    [No Abstract] [Full Text] [Related]

  • 5. Dopaminergic nervous transmission in Parkinson's disease.
    Rinne UK, Sonninen V, Riekkinen P, Laaksonen H.
    Med Biol; 1974 Jun 02; 52(3):208-17. PubMed ID: 4371255
    [No Abstract] [Full Text] [Related]

  • 6. [Biochemical bases for the treatment of Parkinson's syndrome with L-dopa].
    Pletscher A, Bartholini G, Gey KF, Jenni A.
    Schweiz Med Wochenschr; 1970 May 09; 100(19):797-804. PubMed ID: 4924275
    [No Abstract] [Full Text] [Related]

  • 7. [The therapeutic use of L-DOPA in Parkinson's disease. Biochemical, pharmacological and clinical considerations].
    Morselli PL, Rizzo M, Tognoni G.
    Recenti Prog Med; 1970 Feb 09; 48(2):97-124. PubMed ID: 5467589
    [No Abstract] [Full Text] [Related]

  • 8. [Etiology and therapy of Parkinson's syndrome and related pharmacological concepts shown in experimental models].
    Oehme P, Schwarz K.
    Dtsch Gesundheitsw; 1966 Apr 28; 21(17):792-8. PubMed ID: 5929188
    [No Abstract] [Full Text] [Related]

  • 9. [Dopaminergic conception of Parkinsonism and its treatment with L-DOPA].
    Levin SL.
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1972 Apr 28; 72(9):1418-26. PubMed ID: 4349303
    [No Abstract] [Full Text] [Related]

  • 10. Effect of L-dopa on brain monoamines and their metabolites in Parkinson's disease.
    Rinne UK, Sonninen V, Hyyppä M.
    Life Sci I; 1971 May 15; 10(10):549-57. PubMed ID: 5580101
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Modifications of catecholamine metabolism under the effect of a decarboxylase inhibitor associated with L-dopa and desipramine in patients with depressive and parkinsonian syndromes].
    Geissbuhler F, Bartholini G, Gaillard JM, Tissot R.
    Encephale; 1971 May 15; 60(3):189-209. PubMed ID: 5119348
    [No Abstract] [Full Text] [Related]

  • 13. L-dopa in Parkinson's disease. A report on 95 cases and review of the literature.
    Lewis I.
    J Med Assoc State Ala; 1971 May 15; 40(11):709-18. PubMed ID: 5573008
    [No Abstract] [Full Text] [Related]

  • 14. Evaluation of L-dopa therapy in Parkinson's disease.
    Mones RJ, Elizan TS, Siegel GJ.
    N Y State J Med; 1970 Sep 15; 70(18):2309-18. PubMed ID: 5272106
    [No Abstract] [Full Text] [Related]

  • 15. [Effect of aminazin on the content of adrenaline, nordrenaline, dopamine and dopa in rat tissue in closed cranio-cerebral trauma].
    Matlina ESh, Rakhmanova TB.
    Farmakol Toksikol; 1969 Sep 15; 32(2):138-40. PubMed ID: 5772133
    [No Abstract] [Full Text] [Related]

  • 16. L-DOPA, catecholamines, and behavior: a clinical and biochemical study in depressed patients.
    Goodwin FK, Murphy DL, Brodie HK, Bunney WE.
    Biol Psychiatry; 1970 Oct 15; 2(4):341-66. PubMed ID: 4920729
    [No Abstract] [Full Text] [Related]

  • 17. [Treatment of Parkinson's disease with L-dopa and with a combination of L-dopa and dopa-decarboxylase inhibitor].
    Agnoli A, Casacchia M, Reitano M, Ruggieri S, Barba C, Zamponi A.
    Minerva Med; 1972 Dec 12; 63(89):4853-61. PubMed ID: 4566743
    [No Abstract] [Full Text] [Related]

  • 18. [L-Dopa therapy in Parkinson's disease. A double-blind study].
    Worm-Petersen J, Dupont E, Mikkelsen B.
    Ugeskr Laeger; 1971 Nov 26; 133(47):2321-6. PubMed ID: 4944651
    [No Abstract] [Full Text] [Related]

  • 19. [Normal and pathological sleep. Clinical and experimental cases in relation to catecholamines during the use of L-Dopa].
    Delmar A, Kuziora IF, Pozzo R, D'Alberto N, Di Marco M.
    Prensa Med Argent; 1970 Oct 30; 57(35):1649-53. PubMed ID: 4396056
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.